200 related articles for article (PubMed ID: 32831069)
21. Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.
Caldas IS; Menezes APJ; Diniz LF; Nascimento ÁFDSD; Novaes RD; Caldas S; Bahia MT
Acta Trop; 2019 Jan; 189():30-38. PubMed ID: 30290285
[TBL] [Abstract][Full Text] [Related]
22. Direct evidence gap on fixed versus adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: Systematic review and individual patient data meta-analysis.
Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Villar JC; Reidel S; Gibbons L; Sosa-Estani S
Trop Med Int Health; 2023 Jan; 28(1):2-16. PubMed ID: 36420767
[TBL] [Abstract][Full Text] [Related]
23. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
24. Thioridazine aggravates skeletal myositis, systemic and liver inflammation in Trypanosoma cruzi-infected and benznidazole-treated mice.
Mendonça AAS; Gonçalves-Santos E; Souza-Silva TG; González-Lozano KJ; Caldas IS; Gonçalves RV; Diniz LF; Novaes RD
Int Immunopharmacol; 2020 Aug; 85():106611. PubMed ID: 32447223
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR.
Murcia L; Simón M; Carrilero B; Roig M; Segovia M
J Infect Dis; 2017 May; 215(9):1452-1458. PubMed ID: 28201741
[TBL] [Abstract][Full Text] [Related]
27. Detection of Trypanosoma cruzi and Treatment Monitoring by PCR from Dried Blood Spot Samples in Children.
Sánchez AG; Alvarellos E; Kohout I; Rodriguez Schulz DG; Cordeiro E; Caeiro JP; Alvarellos T
Rev Fac Cien Med Univ Nac Cordoba; 2016; 73(3):176-180. PubMed ID: 27805554
[TBL] [Abstract][Full Text] [Related]
28. Schistosoma mansoni co-infection modulates Chagas disease development but does not impair the effect of benznidazole-based chemotherapy.
Lozano KJG; Gonçalves Santos E; Vilas Boas DF; Oliveira RRG; Diniz LF; Benedetti MD; Carneiro CM; C Bandeira L; Faria G; Gonçalves RV; Novaes RD; Caldas S; Caldas IS
Int Immunopharmacol; 2024 Feb; 128():111467. PubMed ID: 38211479
[TBL] [Abstract][Full Text] [Related]
29. Human infectiousness and parasite load in chronic patients seropositive for Trypanosoma cruzi in a rural area of the Argentine Chaco.
Macchiaverna NP; Enriquez GF; Bua J; Fernández MP; Sartor PA; Gürtler RE; Cardinal MV
Infect Genet Evol; 2020 Mar; 78():104062. PubMed ID: 31683004
[TBL] [Abstract][Full Text] [Related]
30. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission.
Sosa-Estani S; Cura E; Velazquez E; Yampotis C; Segura EL
Rev Soc Bras Med Trop; 2009; 42(5):484-7. PubMed ID: 19967227
[TBL] [Abstract][Full Text] [Related]
31. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity.
Zingales B
Acta Trop; 2018 Aug; 184():38-52. PubMed ID: 28941731
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole.
Franco LAM; Moreira CHV; Buss LF; Oliveira LC; Martins RCR; Manuli ER; Lindoso JAL; Busch MP; Pereira AC; Sabino EC
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669428
[TBL] [Abstract][Full Text] [Related]
33. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
[TBL] [Abstract][Full Text] [Related]
34. Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study.
Scarim CB; de Andrade CR; da Rosa JA; Dos Santos JL; Chin CM
Int J Exp Pathol; 2018 Oct; 99(5):236-248. PubMed ID: 30320480
[TBL] [Abstract][Full Text] [Related]
35. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.
Gruendling AP; Massago M; Teston AP; Monteiro WM; Kaneshima EN; Araújo SM; Gomes ML; Barbosa Md; Toledo MJ
Am J Trop Med Hyg; 2015 Jun; 92(6):1178-89. PubMed ID: 25940197
[TBL] [Abstract][Full Text] [Related]
36. Chagas cardiomyopathy: The potential effect of benznidazole treatment on diastolic dysfunction and cardiac damage in dogs chronically infected with Trypanosoma cruzi.
Santos FM; Mazzeti AL; Caldas S; Gonçalves KR; Lima WG; Torres RM; Bahia MT
Acta Trop; 2016 Sep; 161():44-54. PubMed ID: 27215760
[TBL] [Abstract][Full Text] [Related]
37. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
Morillo CA; Marin-Neto JA; Avezum A; Sosa-Estani S; Rassi A; Rosas F; Villena E; Quiroz R; Bonilla R; Britto C; Guhl F; Velazquez E; Bonilla L; Meeks B; Rao-Melacini P; Pogue J; Mattos A; Lazdins J; Rassi A; Connolly SJ; Yusuf S;
N Engl J Med; 2015 Oct; 373(14):1295-306. PubMed ID: 26323937
[TBL] [Abstract][Full Text] [Related]
38. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics.
Trochine A; Creek DJ; Faral-Tello P; Barrett MP; Robello C
PLoS Negl Trop Dis; 2014 May; 8(5):e2844. PubMed ID: 24853684
[TBL] [Abstract][Full Text] [Related]
39. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
[TBL] [Abstract][Full Text] [Related]
40. Candimine from Hippeastrum escoipense (Amaryllidaceae): Anti-Trypanosoma cruzi activity and synergistic effect with benznidazole.
Ortiz JE; Piñeiro M; Martinez-Peinado N; Barrera P; Sosa M; Bastida J; Alonso-Padilla J; Feresin GE
Phytomedicine; 2023 Jun; 114():154788. PubMed ID: 37037085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
